On November 8 and 9, the Josep Carreras Leukaemia Research Institute hosted the fourth edition of the Preceptorship, the advanced training project organized by Dr. Josep Maria Ribera, principal investigator of the Acute Lymphoblastic Leukemia (ALL) research group, director of the Stem Cell Transplant Unit of the Germans Trias i Pujol University Hospital (HUGTP) and head of the clinical haematology service of the Catalan Institute of Oncology (ICO).

The course, attended by a small group of highly specialized international physicians, reviewed and updated the latest scientific advances in the biology and treatment of ALL, both B and T cells, through lectures by top-level speakers and the revision of clinical cases. The sessions were held with the support of the biopharmaceutical company Incyte.

According to Dr. Ribera, the importance of these specialized courses lies in the fact that "the increasingly deep knowledge of the biology of acute lymphoblastic leukaemia (ALL), both T and B, is leading to the application of more specific and personalized treatments" and points out that "the most important advances in the treatment of ALL consist of immunotherapy and therapy directed at molecular targets, preferably in combination."

Thanks to courses such as Dr. Ribera's Preceptorship, the next generations of professionals in the field of oncohaematology are better prepared than ever to apply the latest scientific knowledge in both the diagnosis and treatment of diseases.